Related Experiment Video
Updated: Feb 11, 2026
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Prediction of response to targeted and immune checkpoint therapies
Edward D Blair1, Martina Kaufmann2, Mieke Keppens3
1Integrated Medicines Ltd, Topfield House, Ermine Street, Caxton, Cambridge, CB23 3PQ, UK.
Abstract:
Targeted therapies continue to be key components of cancer treatment. New approaches to detection of acquired resistance at the genomic level, in combination with new therapies, help to overcome the challenges that are seen frequently, rapidly and broadly across tumor pathologies, and provide opportunities for cancer management. In the last several years, a new breed of modalities called immune checkpoint inhibitors have come to the forefront of clinically effective treatments. A plethora of rapid approvals and early access initiatives have seen anti-cytotoxic T-lymphocyte-associated antigen-4, and particularly anti-programmed death receptor-1 therapies, deployed in a number of tumor indications of high unmet need. With the rise of immune checkpoint inhibition, and the broader resurgence in the immuno-oncology field, we are facing challenges in the prediction of response.
Insights
Targeted cancer therapies and immune checkpoint inhibitors show promise. Predicting patient response to these advanced treatments remains a significant challenge in immuno-oncology.
Area of Science:
- Oncology
- Immunotherapy
- Genomics
Background:
- Targeted therapies are crucial in cancer treatment.
- Genomic-level detection of acquired resistance aids in overcoming treatment challenges.
- Immune checkpoint inhibitors, including anti-cytotoxic T-lymphocyte-associated antigen-4 and anti-programmed death receptor-1 therapies, are emerging as effective treatments for various cancers.
Discussion:
- The rise of immune checkpoint inhibition has revitalized the immuno-oncology field.
- Predicting patient response to these novel therapies is a key challenge.
- Integrating genomic resistance detection with new therapeutic strategies is essential for effective cancer management.
Key Insights:
- New methods for detecting acquired genomic resistance are vital.
- Immune checkpoint inhibitors offer new avenues for cancer treatment.
- Challenges exist in predicting treatment response in immuno-oncology.
Outlook:
- Further research is needed to improve response prediction for immune checkpoint inhibitors.
- Combining genomic insights with advanced therapies can enhance cancer management.
- Continued development in immuno-oncology holds promise for future cancer treatments.
More Related Videos
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
10:21Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
Published on: February 23, 2024
Related Concept Videos
01:36Humoral Immune Responses
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:40Cell-mediated Immune Responses
01:23Cells of the Adaptive Immune Response
01:29Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
01:28Cells of the Innate Immune Response
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...